WEE1 inhibitor can selectively inhibit the proliferation of glioma and hepatocellular carcinoma cells with ATRX mutations, which indicates that the synthetic lethal interaction between ATRX and WEE1 can be applied in an extensive range of tumors. This evidence concerns the gene WEE1 and central nervous system cancer.